What are the main functions and effects of serputinib/serpatinib? What are the indications?

Selpercatinib is a new type of oral small molecule targeted drug that is a highly selective RET tyrosine kinase inhibitor. RET gene mutations or fusions play an important role in a variety of malignant tumors , but traditional chemotherapy or broad-spectrum targeted drugs are often unable to effectively control such gene-driven cancers. The development of seputinib is a breakthrough attempt to inhibit the RET gene pathway in a medical context. It inhibits the proliferation and metastasis of tumor cells by blocking RET kinase signaling, thereby providing more targeted treatments for RET-driven cancer patients.

The scope of approved indications is relatively wide, covering non-small cell lung cancer (NSCLC), thyroid cancer and other solid tumors driven by RET gene abnormalities. First, in RET fusion-positive non-small cell lung cancer (NSCLC), seputinib has been approved by the FDA for the treatment of locally advanced or metastatic cases. Non-small cell lung cancer is the most common type of lung cancer. Traditional treatment methods include chemotherapy, immunotherapy and other targeted drugs. However, for the special molecular subtype of RET fusion, cepotinib has shown a more precise and effective inhibitory effect, bringing new options to this type of patients.

Secondly, in the treatment of RET-mutant medullary thyroid carcinoma (MTC), seputinib also shows significant advantages. The drug can be used for advanced or metastatic patients aged 12 years and older who carry RET mutations and who often require systemic treatment. Medullary thyroid cancer is a rare and malignant subtype of thyroid cancer for which traditional treatments are limited. However, the discovery of RET mutations makes seputinib one of the first highly targeted treatment options.

The third category of indications is RET fusion-positive thyroid cancer (TC). It is suitable for children and adult patients aged 12 years and above, especially those with advanced or metastatic disease that are not sensitive to radioactive iodine therapy. For such patients, seputinib can be an important option for systemic treatment, thus breaking through the previous limitations of lack of effective drugs after radioactive iodine resistance.

In addition to lung cancer and thyroid cancer, the application scope of seputinib has been further expanded to Other RET fusion-positive solid tumors. These patients often have disease progression despite prior systemic therapy or lack suitable alternatives. The approval of seputinib provides new hope for patients with these rare solid tumors. Although the number of this group of people is relatively small, in the field of clinical oncology, meeting the needs for "orphan drug" indications has extremely high medical value and social significance.

Overall, the main efficacy and role of seputinib is precise inhibition ofRET-driven cancer growth. Compared with traditional broad-spectrum inhibitors, its high selectivity for molecular targets not only improves efficacy, but also reduces some non-target side effects, thereby improving patient tolerance and quality of life. As a targeted drug, its efficacy requires clear genetic testing. Therefore, in clinical practice, the application of seputinib must rely on genetic testing methods to ensure that patients do have RET mutations or fusions.

Reference:https://en.wikipedia.org/wiki/Selpercatinib